Werewolf Therapeutics Files 8-K for Financial Results
Ticker: HOWL · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001785530
| Field | Detail |
|---|---|
| Company | Werewolf Therapeutics, Inc. (HOWL) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2026 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-k
TL;DR
Werewolf Therapeutics dropped its Q1 2026 financial results on 8-K.
AI Summary
Werewolf Therapeutics, Inc. filed an 8-K on March 27, 2026, reporting results of operations and financial condition. The filing includes financial statements and exhibits, with the primary document being the 8-K itself in iXBRL format.
Why It Matters
This filing provides investors with the latest financial performance and condition of Werewolf Therapeutics, Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial results and does not indicate any unusual risks.
Key Players & Entities
- Werewolf Therapeutics, Inc. (company) — Filer of the 8-K
- 0001785530 (company) — CIK number for Werewolf Therapeutics, Inc.
- 2026-03-27 (date) — Filing date of the 8-K
FAQ
What specific financial information is being reported in this 8-K filing?
The 8-K filing reports on the 'Results of Operations and Financial Condition' as per Item 2.02 and includes 'Financial Statements and Exhibits' as per Item 9.01.
When was this 8-K filing accepted by the SEC?
The 8-K filing was accepted by the SEC on March 27, 2026, at 07:07:34.
What is the CIK number for Werewolf Therapeutics, Inc.?
The CIK number for Werewolf Therapeutics, Inc. is 0001785530.
What are the primary document types included in this filing?
The primary document types include an iXBRL 8-K, an exhibit (EX-99.1), and a graphic file (werewolflogohorizontala.jpg).
What is the business address and contact number for Werewolf Therapeutics, Inc.?
The business address is 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472, and the contact number is 617-952-0555.
Filing Stats: 1,069 words · 4 min read · ~4 pages · Grade level 15.7 · Accepted 2026-03-27 07:07:34
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share HOWL The Nasdaq G
Filing Documents
- howl-20260327.htm (8-K) — 30KB
- a12312025ex991.htm (EX-99.1) — 57KB
- werewolflogohorizontala.jpg (GRAPHIC) — 271KB
- 0001785530-26-000005.txt ( ) — 588KB
- howl-20260327.xsd (EX-101.SCH) — 2KB
- howl-20260327_lab.xml (EX-101.LAB) — 23KB
- howl-20260327_pre.xml (EX-101.PRE) — 13KB
- howl-20260327_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 27, 2026, Werewolf Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release announcing financial results for the quarter ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release issued by the Company on March 27, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Note Regarding Forward-Looking Statements Any statements in this Current Report on Form 8-K about the Company's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to substantial risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include statements regarding the Company's strategy, future operations, prospects, plans, objectives of management, including potential strategic partnerships, the Company's exploration and evaluation of strategic alternatives and the ability of any such strategic alternative to provide stockholder value, the projection of the cash runway, the expected timeline for the preclinical and clinical development of product candidates and the availability of data from such preclinical and clinical development, the potential activity and efficacy of product candidates in preclinical studies and clinical trials, and the anticipated safety profile of product candidates. The words "aim," "anticipate," "approach," "believe," "contemplate," "continue," "could," "design," "designed to," "engineered," "estimate," "expect," "goal," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "promise," "should," "target," "will," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEREWOLF THERAPEUTICS, INC. Date: March 27, 2026 By: /s/ Michael Urban Michael Urban Vice President of Finance and Corporate Controller